Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Income towards Parent Company (2016 - 2026)

Cumberland Pharmaceuticals' Income towards Parent Company history spans 15 years, with the latest figure at -$1.1 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company rose 32.41% to -$1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.1 million, a 32.41% increase, with the full-year FY2025 number at -$2.5 million, up 59.03% from a year prior.
  • Income towards Parent Company hit -$1.1 million in Q4 2025 for Cumberland Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for CPIX hit a ceiling of $1.2 million in Q1 2025 and a floor of -$6.3 million in Q4 2023.
  • Historically, Income towards Parent Company has averaged -$794191.7 across 4 years, with a median of -$899213.0 in 2023.
  • Biggest five-year swings in Income towards Parent Company: crashed 1204.25% in 2024 and later surged 165.61% in 2025.
  • Tracing CPIX's Income towards Parent Company over 4 years: stood at $503318.0 in 2021, then plummeted by 1352.09% to -$6.3 million in 2023, then surged by 74.66% to -$1.6 million in 2024, then skyrocketed by 32.41% to -$1.1 million in 2025.
  • Business Quant data shows Income towards Parent Company for CPIX at -$1.1 million in Q4 2025, -$1.9 million in Q3 2025, and -$735207.0 in Q2 2025.